mProX™ Human GPR35 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- GPCR Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human GPR35 Stable Cell Line (S01YF-0923-PY165). Click the button above to contact us or submit your feedback about this product.
Jennifer (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Jason (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 The suppression of GPR35 resulted in a reduction of the suppressive impact of CID-2745687 on the activity of YAP/TAZ, thus demonstrating the intricate interplay between these factors.
The researchers investigated the impact of CID treatment on LS174T cells with and without GPR35 knockdown after a 3-hour exposure. It was observed that YAP phosphorylation levels exhibited a dose-dependent increase in the control group, whereas TAZ expression showed a corresponding decrease following CID treatment. Interestingly, these cellular responses were noticeably attenuated in the LS174T cells with GPR35 knockdown, highlighting the role of GPR35 in modulating CID-induced effects.
Ref: Otkur, Wuxiyar, et al. "GPR35 antagonist CID-2745687 attenuates anchorage-independent cell growth by inhibiting YAP/TAZ activity in colorectal cancer cells." Frontiers in Pharmacology 14 (2023): 1126119.
Pubmed: 37113762
DOI: 10.3389/fphar.2023.1126119
Research Highlights
Li T, et al. "Fasting-mimicking diet alleviates inflammatory pain by inhibiting neutrophil ." Cell communication and signaling : CCS, 2023.
Neutrophil Extracellular Traps (NETs) have been found to play a role in promoting neuroinflammation and central nervous system (CNS) disease progression. However, it is still unclear whether CNS-associated NETs have an impact on pain outcomes. Previous studies have shown that a fasting-mimicking diet (FMD) can alleviate neurological disorders by reducing neuroinflammation and promoting nerve regeneration. In this study, the researchers aimed to investigate the effects of NETs in the CNS during acute pain and the role of FMD in inhibiting NETs and relieving pain. To achieve this, the researchers established an inflammatory pain model in mice and employed various methods such as PAD4 siRNA, CI-amidine (PAD4 inhibitor), AAV-GFAP-shRNA, AAV-hSyn-shRNA, and selegiline (MAO-B inhibitor) to inhibit the formation of NETs. They also examined changes in NETs, neuroinflammation, and related signaling pathways through various techniques such as western blot, immunofluorescence, ELISA, and flow cytometry. The results showed that in the acute phase of inflammatory pain, NETs accumulated in the spinal cords of mice, which was associated with increased neuroinflammation. Inhibiting NETs formation was found to alleviate allodynia and neuroinflammation in the mice. FMD was also shown to inhibit NETs production and alleviate inflammatory pain, which was further enhanced by treatment with the NETs inhibitor CI-amidine and reversed by treatment with the NETs inducer phorbol 12-myristate 13-acetate (PMA). The researchers also found that the neutrophil-recruiting pathway MAO-B/5-hydroxyindoleacetic acid (5-HIAA) / G-protein-coupled receptor 35 (GPR35) and NETs-inducing pathway MAO-B/ Reactive oxygen species (ROS) were significantly upregulated during the development of inflammatory pain. Further investigation revealed that MAO-B was largely expressed in astrocytes and neurons in the spinal cords of mice with CFA-induced inflammatory pain. However, inhibiting or knocking down MAO-B was found to effectively attenuate inflammatory pain, NETs formation, and neuroinflammation in the spinal cords. In addition, the researchers performed rescue experiments and found that MAO-B inhibitors synergistically enhanced the pain relief and NETs inhibition induced by FMD
Pubmed:
37735678
DOI:
10.1186/s12964-023-01258-2
Nakashima F, et al. "Eriodictyol and thymonin act as GPR35 agonists.." Bioscience, biotechnology, and biochemistry, 2023.
In this study, the authors aimed to identify potential GPR35 agonists among 19 different herbs and spices in order to understand the mechanisms behind their reported health benefits. Through screening, they found that the ethyl acetate extract of thyme exhibited significant GPR35 agonistic activity. Further analysis revealed that two polyphenolic compounds, eriodictyol and thymonin, were responsible for this activity. Both compounds showed potent and specific agonist activity toward GPR35. These findings suggest that eriodictyol and thymonin may have beneficial health effects through GPR35 activation.
Pubmed:
37667527
DOI:
10.1093/bbb/zbad125